ArtBio announced today that it closed a $132 million Series B funding round to advance its development of alpha radioligand therapies (ARTs). New investors Sofinnova Investments and B Capital, along with a life sciences-dedicated investment fund that previously invested, led the round. Existing investors F-Prime, Omega Funds and Third Rock Ventures, plus new investors Qatar…